Survivin in cancer health disparities
Khan S, Ferguson Bennit H, Asuncion Valenzuela MM, Turay D, Diaz Osterman CJ, Moyron RB, Esebanmen GE, Ashok A, Wall NR (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 8, 2015 Category: Biochemistry Source Type: research
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
In this study, which led to the approval of nintedanib, addition of nintedanib to docetaxel significantly improved overall survival in patients with adenocarcinoma histology. Nintedanib demonstrated a manageable safety profile in combination with docetaxel. This review focuses on the clinical experience with nintedanib in NSCLC and discusses the clinical potential of this agent for use in combination with chemotherapy. Keywords: nintedanib, non-small cell lung cancer, second-line treatment, docetaxel, adenocarcinoma, antiangiogenesis (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 1, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Nintedanib in management of NSCLC
Reck M, Mellemgaard A (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 1, 2015 Category: Biochemistry Source Type: research
New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis Corrigendum
Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno GB, Incorvaia C (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - June 29, 2015 Category: Biochemistry Source Type: research
Biologic monotherapy in the treatment of rheumatoid arthritis
Jacqueline Detert, Pascal Klaus Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, ...
Source: Biologics: Targets and Therapy - May 14, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Safety and effectiveness in biological monotherapy in RA
Detert J, Klaus P (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - May 13, 2015 Category: Biochemistry Source Type: research
Role of biologics in intractable urticaria
Andrew Cooke,1 Adeeb Bulkhi,1,2 Thomas B Casale1 1Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 2Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia Abstract: Chronic urticaria (CU) is a common condition faced by many clinicians. CU has been estimated to affect approximately 0.5%–1% of the population, with nearly 20% of sufferers remaining symptomatic 20 years after onset. Antihistamines are the first-line therapy for CU. Unfortunately, nearly half of these patients will fail this first-line therapy and...
Source: Biologics: Targets and Therapy - April 13, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Biologics in intractable urticaria
Cooke A, Bulkhi A, Casale TB (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - April 12, 2015 Category: Biochemistry Source Type: research
Response Ponatinib1 for resistant mutations in CML and Ph ALL
Bardy-Bouxin N, Matczak E, Devgan G, Woloj M, Shapiro M (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - February 18, 2015 Category: Biochemistry Source Type: research
